Townsend Richard Nolan 4
4 · Lexeo Therapeutics, Inc. · Filed Sep 16, 2025
Insider Transaction Report
Form 4
Townsend Richard Nolan
DirectorChief Executive Officer
Transactions
- Award
Common Stock
2025-09-12$2.64/sh+2,193$5,798→ 222,251 total
Footnotes (2)
- [F1]The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
- [F2]Includes 131,092 Restricted Stock Units.